NSABP FC‐6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wild‐type liver metastases receiving mFOLFOX7 plus cetuximab
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.27078
Abstract: This study sought to determine the R0 resection rate in KRAS wild‐type (WT), liver‐only metastatic colorectal cancer (CRC) patients initially identified as having unresectable disease who were treated with FOLFOX7 plus cetuximab. Exploratory molecular analyses… read more here.
Keywords: kras wild; type liver; rate; colorectal cancer ... See more keywords
Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-91330-z
Abstract: KRAS status serves as a predictive biomarker of response to treatment in metastatic colorectal cancer (mCRC). We hypothesize that complex interactions between multiple pathways contribute to prognostic differences between KRAS wild-type and KRAS mutant patients… read more here.
Keywords: metastatic colorectal; kras wild; colorectal cancer; kras mutant ... See more keywords
Triple targeting of HER receptors overcomes heregulin-mediated resistance to EGFR blockade in colorectal cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular cancer therapeutics"
DOI: 10.1158/1535-7163.mct-21-0818
Abstract: Current treatment options for patients with advanced colorectal cancers (CRC) include anti-EGFR/HER1 therapy with the blocking antibody cetuximab. Although a subset of patients with KRAS wild-type disease initially respond to the treatment, resistance develops in… read more here.
Keywords: kras wild; triple targeting; resistance; egfr ... See more keywords
Cetuximab (CTX) in first-line treatment of elderly patients with metastatic colorectal cancer (mCRC), KRAS wild type: French multicentre prospective community-based registry and results.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.4_suppl.760
Abstract: 760Background: Pts included in clinical trials represent the unusual population in mCRC. This study aims to provide oncologist with a better understanding of the potential benefit of CT with CTX in older patients with mCRC… read more here.
Keywords: prospective community; kras wild; french multicentre; multicentre prospective ... See more keywords
Concurrent Mutations in STK11 and KEAP1 Cause Treatment Resistance in KRAS Wild-type Non-small-cell Lung Cancer.
Sign Up to like & getrecommendations! Published in 2023 at "Internal medicine"
DOI: 10.2169/internalmedicine.1110-22
Abstract: We herein report a patient with KRAS wild-type non-small-cell lung cancer (NSCLC) with concurrent STK11 and KEAP1 mutations. A 53-year-old man visited a local doctor with a complaint of left shoulder swelling and pain. He… read more here.
Keywords: kras wild; stk11 keap1; resistance; wild type ... See more keywords